Janus Henderson Group PLC grew its stake in Insulet Co. (NASDAQ:PODD) by 1.1% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 379,392 shares of the medical instruments supplier’s stock after purchasing an additional 4,239 shares during the period. Janus Henderson Group PLC owned about 0.64% of Insulet worth $40,197,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently bought and sold shares of the company. Chicago Equity Partners LLC acquired a new stake in Insulet in the 2nd quarter worth $375,000. Oppenheimer Asset Management Inc. acquired a new stake in Insulet in the 2nd quarter worth $300,000. Paloma Partners Management Co grew its position in Insulet by 2,104.4% in the 2nd quarter. Paloma Partners Management Co now owns 168,699 shares of the medical instruments supplier’s stock worth $14,458,000 after purchasing an additional 161,046 shares during the last quarter. OppenheimerFunds Inc. grew its position in Insulet by 26.6% in the 2nd quarter. OppenheimerFunds Inc. now owns 791,702 shares of the medical instruments supplier’s stock worth $67,848,000 after purchasing an additional 166,585 shares during the last quarter. Finally, State of Wisconsin Investment Board grew its position in Insulet by 78.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 71,482 shares of the medical instruments supplier’s stock worth $6,126,000 after purchasing an additional 31,482 shares during the last quarter.
In other news, SVP David Colleran sold 6,113 shares of Insulet stock in a transaction that occurred on Wednesday, November 14th. The shares were sold at an average price of $80.41, for a total transaction of $491,546.33. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Aiman Abdel-Malek sold 602 shares of Insulet stock in a transaction that occurred on Wednesday, November 14th. The stock was sold at an average price of $80.41, for a total transaction of $48,406.82. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 10,013 shares of company stock valued at $856,934. Insiders own 3.60% of the company’s stock.
Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 1st. The medical instruments supplier reported $0.03 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.01. Insulet had a negative net margin of 2.54% and a negative return on equity of 7.63%. The company had revenue of $151.10 million during the quarter, compared to the consensus estimate of $148.82 million. During the same period in the previous year, the firm posted ($0.04) earnings per share. The company’s revenue was up 24.1% on a year-over-year basis. On average, equities research analysts anticipate that Insulet Co. will post -0.05 earnings per share for the current year.
PODD has been the subject of a number of analyst reports. BidaskClub raised shares of Insulet from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 11th. Leerink Swann reaffirmed an “outperform” rating and set a $130.00 price objective on shares of Insulet in a report on Tuesday, September 11th. Zacks Investment Research raised shares of Insulet from a “hold” rating to a “buy” rating and set a $119.00 price objective for the company in a report on Monday, October 1st. Oppenheimer set a $100.00 price objective on shares of Insulet and gave the stock a “hold” rating in a report on Friday, November 2nd. Finally, Morgan Stanley lifted their price target on shares of Insulet from $96.00 to $105.00 and gave the company an “equal weight” rating in a report on Thursday, October 11th. One analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $101.44.
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.
Featured Article: How is the discount rate different from the Federal Funds rate?
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.